Skip to content
MARKETS / BALCAO / BLGO
BALCAO · CHEMICALS & ALLIED PRODUCTS · SMALL CAP

Biolargo, Inc. BLGO

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.8M
▼ 56.3% YoY
$-15.2M
In brief

What this company does

We invent, develop, then commercialize technologies that tackle difficult challenges in air quality, water, environmental engineering, battery energy storage, and advanced antimicrobial medical device platforms. Our model is to invent new technologies that solve specific problems, develop them and prove they work, and then commercialize them with purpose-suited subsidiaries, identify and secure the right partnerships to increase their commercial reach, or potentially sell the intellectual property. We operate our business in distinct business segments: ● Odor and VOC control products, including consumer pet and household products and CupriDyne Clean Industrial Odor Eliminator, sold by our wholly-owned subsidiary ONM Environmental, Inc.;

Written from the business description in BioLargo, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth
USD 7.8M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.8 · Net income -15.2
8M16M-8M201020122014201620182020202220242025
Compound annual growth
+9.7%
+26.1%
+50.8%
+29.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +26.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−196 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -191.3% · Net -195.6%
-5000%201020122014201620182020202220242025
ROE

No chart to show — the reason differs by year; see each year in the table below.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2017 · FCF -4.3
-2M-4M201020122014201620182020202220242025

Total assetsUSD 8.3M
EquityUSD 4.0M
CashUSD 3.9M
Gross debtUSD 2.1M
Net debtUSD -1.8M
Current ratio1.01×

The company holds more cash than debt.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

The share count changed between 2016 and 2022, but the exact year can't be marked here — the underlying count wasn't on file for every year in that stretch.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0···−0.0−0.0−0.0−0.0−0.0·−0.0−0.0·
Income tax $B·0.00.0·············
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B········−0.0·····−0.0·
EPS, diluted $····−0.03−0.05−0.08−0.09−0.10−0.09−0.06−0.05−0.04−0.08−0.07−0.13
Dividend / sh $················
Payout %················
ROE %················
Shares out B··0.290.28·····0.09·0.080.080.070.06·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityChemicals & Allied Products
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image